Kenneth L. Waggoner, Chief Executive Officer and President:
Kenneth L. Waggoner has almost four decades of experience in management, business, operations and law. Mr. Waggoner started his career as an attorney in private practice. Notably he was a senior partner with Brobeck, Phleger and Harrison, named one of the top two law firms worldwide that provide services to biotechnology clients including Chiron, Amgen, Biogen Idec, Sangamo, Ligand, DepoTech and many others. He was the Managing Partner of Brobeck’s Los Angeles office. Mr. Waggoner was also a member of the Executive Committee for almost ten years and on the Policy Committee for numerous years managing Brobeck’s worldwide operations with annual revenues in excess of $750,000,000. While at Brobeck, Mr. Waggoner was the Co-Chairman of Brobeck’s world-wide Environmental Law Group.
Further highlights of Mr. Waggoner’s career include leadership and legal positions with several start-up companies during the last several years as well as working with Fortune 500 companies most of his professional career. During his tenure with Chevron, Mr. Waggoner served as the Vice President and General Counsel of its Global Downstream operations where he was responsible for the overall management of legal services to the North American, Latin American, Europe and Asian Products Companies. At Chevron he led a successful restructuring of the company’s international Legal Department following Chevron’s acquisition of Texaco.
Mr. Waggoner received his Juris Doctorate. with honors in 1973 from Loyola University School of Law in Los Angeles.
Gerald W. Crabtree, Ph.D. – Chief Operating Officer and Director:
Dr. Crabtree is the Company’s Chief Operating Officer. Since 1985, Dr. Crabtree has been involved with various biopharmaceutical companies where he has alternatively supervised and coordinated the development of multiple drug candidates, prepared clinical protocols, investigator brochures, monographs, research and review articles and served as project manager for development of major oncologic agents. He is a Member of the American Society of Clinical Oncology and also is a past member of research grant review committees for the National Institute of Health and the American Cancer Society. Dr. Crabtree established and directed, from inception, a department that monitored and coordinated the development of oncologic and immunologic drugs from initial discovery through regulatory approval in a major pharmaceutical company and served as project manager for the development of the anticancer agent, Taxol®.
Dr. Crabtree received his Ph.D. in Biochemistry from the University of Alberta, Edmonton, Alberta, Canada and has published over 80 articles in peer-reviewed journals. He is a National Cancer Institute of Canada Research Fellow. In addition, he served as Department Head of Molecular Pharmacology for the Nucleic Acid Research Institute, and prior to that as Associate Professor of Medicine with the Roger Williams Cancer Center at Brown University. Dr. Crabtree has also served as Director of Project Planning and Management (Oncology/Immunology) at Bristol-Myers Squibb and as Vice-President of Research and Development at ETEX Corporation. Most recently, Dr. Crabtree served as Interim CEO of PhytoCeutica, Inc., where he assisted in preparation and review of FDA documents, clinical study protocols, investment acquisitions and contracts and business plans.
Patricia Gruden – Chief Financial Officer and Chairman of the Board:
Patricia Gruden is the Chief Financial Officer of the Company and Chairman of the Board. Ms. Gruden has made a substantial impact on the Company since its inception. In 1995, Ms. Gruden became cofounder of the company that later became Nuvilex, Inc. The original company was initiated to develop a software program through accurately tracking produce from the field to the table, including the challenges of shipping, temperature variation and maintenance and everything else concerning the distribution of produce worldwide. In addition, the Company developed an ozone cleaning system to kill bacteria on produce without leaving harmful residue on the product and without harming the environment.
Over the years Ms. Gruden has carried out almost every job in the Company, including developer, shipper, President, CEO, Chairman of the Board, CFO and many others. As a result, she has been intricately aware of all aspects of the Company and its products. After a brief semi-retirement in 2009-10, Ms. Gruden returned to make arrangements for necessary funding and to assist the Company in changing from a nutraceutical company to a biotechnology company. Her training has not only included real world experiences of running more than one company, Ms. Gruden embraces every business opportunity with excitement, clarity and focus. Ms. Gruden has a long history of owning her own businesses and doing so successfully. Additionally, a strong community presence allowed her to act as President of the local Chamber of Commerce and Arizona Small Business Association. She has also been active in Habitat for Humanity, shelters for abused women and children and the Ronald McDonald House.